Stay updated on Savolitinib Combo in EGFRm+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page.

Latest updates to the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed descriptions of a clinical study on the combination of savolitinib and osimertinib for treating non-small cell lung cancer, while adding a new interventional model description and a revision note.SummaryDifference40%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 3, 2025.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new last update date of March 25, 2025, and a revision change to v2.14.3, replacing the previous date of February 3, 2025, and revision v2.14.2.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.9%
- Check88 days agoChange DetectedThe webpage has updated its last update information and provided new dates for upcoming events, while also noting that some services may experience heavy traffic affecting performance and availability.SummaryDifference2%
Stay in the know with updates to Savolitinib Combo in EGFRm+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Savolitinib Combo in EGFRm+ NSCLC Clinical Trial page.